Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PDS Biotechnology ( (PDSB) ) just unveiled an update.
On April 15, 2026, PDS Biotechnology announced that interim data from Stage 1 of a National Cancer Institute-led Phase 2 trial of its tumor-targeted IL-12 immunocytokine PDS01ADC in metastatic colorectal cancer were published in the March 10, 2026 issue of JCO Oncology Advances. The study combined subcutaneous PDS01ADC with hepatic artery infusion pump therapy using floxuridine in patients with unresectable microsatellite stable or mismatch repair-proficient colorectal liver metastases who had failed at least one prior chemotherapy regimen.
Among the first nine colorectal cancer patients in the 22-patient cohort, the combination produced a 77.8% objective response rate at six months and an estimated 24-month survival rate of about 85%, compared with 35% response and roughly 40% two-year survival in a parallel trial without PDS01ADC, though no head-to-head study was conducted. Extrahepatic progression-free survival had not been reached at a minimum 13.1-month follow-up versus 8.1 months in the parallel cohort, highlighting potentially meaningful clinical benefit in a population where immune checkpoint inhibitors have historically been ineffective and underscoring PDS Biotech’s bid to strengthen its position in immuno-oncology for hard-to-treat metastatic colorectal cancer.
The most recent analyst rating on (PDSB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
The score is held down primarily by weak financial performance (no meaningful revenue, ongoing losses, negative cash flow, and a sharply more levered 2025 balance sheet). Offsetting this are improved clinical/regulatory visibility from the latest earnings call (accelerated-approval oriented trial amendment and strong cited survival signals) and a technically strong uptrend, though momentum indicators are overbought and valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on PDSB stock, click here.
More about PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company developing targeted cancer treatments aimed at transforming how the immune system detects and kills tumors. Its lead program, PDS0101, is in a pivotal trial for advanced HPV16-positive head and neck squamous cell cancers, and is being studied with immune checkpoint inhibitors and in combinations including its IL-12-based antibody-drug conjugate PDS01ADC. PDS01ADC is in multiple Phase 2 trials across several cancer indications alongside standard-of-care therapies.
Average Trading Volume: 645,772
Technical Sentiment Signal: Sell
Current Market Cap: $60.84M
For a thorough assessment of PDSB stock, go to TipRanks’ Stock Analysis page.